Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 11(64), 2020

DOI: 10.1128/aac.00895-20

Authorea, 2020

DOI: 10.22541/au.158636268.80439895

Links

Tools

Export citation

Search in Google Scholar

Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: A First Approach for the Study of Pharmacologic Sanctuaries

Journal article published in 2020 by Thibaut Gel, Aur lie Barrail Tran, Thibaut Gelé, Hélène L. ne Gouget, Val rie Furlan, Pierre-Hadrien Becker, Anne-Marie Taburet, Olivier Lambotte, Aurélie Barrail-Tran ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

This study aimed to characterize in vitro dolutegravir (DTG) and bictegravir (BIC) binding. They had a preferential binding to human serum albumin (HSA) with two classes of albumin sites. Human alpha-1-acid glycoprotein (HAAG) binding of DTG and BIC showed an atypical nonlinear binding. The low-affinity site on HSA, the main plasma binding protein, suggests that the high protein binding rate should not impair passive diffusion.